Citations

Showing 10 of 108152 citations.

Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome
Lipton, Richard B. , Dodick, David W. , Ailani, Jessica , McGill, Lora, Hirman, Joe, Cady, Roger , Lipton, R.B. , Dodick, David W , Ailani, Jessica

Mayo Clinic

Headache: The Journal of Head and Face Pain | May 20, 2021 | Volume: 61 | Issue: 5 | Pages: 766-776

10.1111/head.14120 | PMID 34013992 Get It

Abstract Objectives To describe the methodology and implications of the patient‐identified most bothersome symptom (PI‐MBS) measure used in the phase 3, multicenter, randomized, double‐blind, placebo‐controlled, and parallel‐group PROMISE‐2 trial and to evaluate the contribution of this measure to the assessment of the preventive migraine benefits of treatment. Background Although freedom from MBS is a coprimary endpoint in acute migraine treatment trials, its evaluation in preventive migraine trials is limited. The PROMISE‐2 study assessed a unique PI‐MBS measure as a secondary endpoint. Methods This was a secondary analysis of data from the PROMISE‐2 study. Adults with chronic migraine (CM) were randomized to receive intravenous (IV) eptinezumab 100 mg, eptinezumab 300 mg, or placebo, administered on day 0 and every 12 weeks. At the screening visit, patients were asked to verbally describe the MBS associated with their CM; the question format was open ended. At subsequent visits, patients were asked to rate the overall change in severity of their MBS from study inception to that time point, using a 7‐point ordinal scale ranging from “very much worse” (−3) to “very much improved” (+3). Patients completed the Patient Global Impression of Change (PGIC) assessment during the same visits, using an identical rating scale and recall period. Endpoints were summarized descriptively; post hoc correlations using the methodologies of Pearson and Spearman were calculated to evaluate relationships between PGIC and PI‐MBS and between PGIC and mean monthly migraine days (MMDs; primary efficacy endpoint in PROMISE‐2). Results Altogether, 1072 patients received treatment (eptinezumab 100 mg, n = 356; eptinezumab 300 mg, n = 350; placebo, n = 366) and were included in the analysis. There were 23 unique MBS identified; those reported by ≥10 patients included light sensitivity (18.7%), nausea/vomiting (15.1%), pain with activity (13.7%), pain (12.4%), headache (11.2%), sound sensitivity (7.3%), throbbing/pulsating pain (4.7%), cognitive disruption (4.1%), fatigue (2.4%), mood changes (1.5%), and sensitivity to smell (0.9%). Four weeks after the first dose (week 4), the rates of much or very much improvement in PI‐MBS were higher with eptinezumab 100 mg (45%) and 300 mg (57%) than with placebo (29%). Four weeks after the second dose (week 16), the proportions with much or very much improvement in PI‐MBS had increased to 58%, 65%, and 36%, respectively. At each time point, the percentages of patients with PGIC ratings of much or very much improved were similar to those for patient‐reported improvement in PI‐MBS. Patient ratings of changes in PI‐MBS and PGIC correlated strongly across time points (Pearson, r range, 0.83–0.88; Spearman, r range, 0.83–0.89); the absolute value of the correlations was greater than the correlation among changes in MMDs and PGIC (Pearson, r range, −0.49 to −0.52; Spearman, r range, −0.49 to −0.52). Conclusions Among patients with CM in the PROMISE‐2 study, a broad range of PI‐MBS was reported at baseline. Throughout the study, patients treated with eptinezumab reported greater improvement in their PI‐MBS severity compared with placebo recipients, and this improvement correlated strongly with PGIC findings. Collectively, these results indicate that PI‐MBS is a promising and novel outcome measure for preventive trials of CM and thus may provide a unique patient‐centered approach for identifying and measuring the burden of migraine symptoms that matter most to each patient, as well as the benefits of treatment.
Examination of Weight-Loss Motivators and Family Factors in Relation to Weight Management Strategies and Dietary Behaviors among Adolescents with Obesity
Biggs, Bridget K. , Wilson, Dawn K. , Quattlebaum, Mary , Kumar, Seema , Meek, Alicia, Jensen, Teresa B. , Kumar, Seema , Biggs, Bridget K

Mayo Clinic

Nutrients | May 20, 2021 | Volume: 13 | Issue: 5 | Pages: 1729

10.3390/nu13051729 | PMID 34065195 Get It

The study aim was to test hypotheses informed by self-determination theory (SDT) regarding associations of adolescent motivators for weight loss and family feeding practices on understanding adolescent weight management and dietary behaviors. Adolescents (n = 71) with obesity were recruited from a large medical center in the Midwest USA and completed questionnaire assessments via an online survey. Results supported hypotheses that endorsement of health motivators for weight loss, conceptualized as autonomous (intrinsic) motivation, and positive family support would be associated with healthier weight management practices and dietary behaviors. Nuanced findings related to social- and self-esteem-related motivators for weight loss indicated a need for further understanding of these weight-loss motivators in the context of SDT. The current study findings highlight the importance of addressing motivational factors and family influences in research and practice related to promoting healthy dietary habits and weight management strategies among adolescents with obesity.
Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data
Otto, Ashley , Rivera, Christina G. , Zeuli, John D. , Temesgen, Zelalem , Otto, Ashley O , Rivera, Christina G

Mayo Clinic

Cells | May 20, 2021 | Volume: 10 | Issue: 5 | Pages: 1263

10.3390/cells10051263 | PMID 34065305 Get It

Contemporary antiretroviral agents afford enhanced potency and safety for patients living with HIV. Newer antiretroviral drugs are often better tolerated than those initially approved in the early stages of the HIV epidemic. While the safety profile has improved, adverse drug reactions still occur. We have segregated the antiretroviral agents used in contemporary practice into class groupings based on their mechanism of antiviral activity (non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors, and entry inhibitors) while providing a review and discussion of the hepatoxicity seen in the most relevant clinical literature published to date. Clinical literature for individual agents is discussed and agent comparisons afforded within each group in tabular format. Our review will provide a summative overview of the incidence and medications associated with hepatic adverse reactions linked to the use of contemporary antiretroviral drugs.
Red blood cell transfusion in a patient with anti-AnWj: a case report
Stowers, Ray E, Richa, Elie M., Stubbs, James R. , Moore, S. Breanndan

Mayo Clinic

Immunohematology | May 20, 2021 | Volume: 23 | Issue: 2 | Pages: 55-58

10.21307/immunohematology-2019-320 Get It

Abstract Anti-AnWj (Anton) has been associated with clinically significant hemolytic transfusion reactions. More than 99 percent of studied populations have RBCs that express the antigen. Reported here is a patient with anti-AnWj who was transfused with antigen-positive RBCs without adverse reaction. Immunohematology 2007; 23:55–58.
Transfusion service disaster planning
Bundy, Kelly, Foss, Mary , Stubbs, James R.

Mayo Clinic

Immunohematology | May 20, 2021 | Volume: 24 | Issue: 3 | Pages: 93-101

10.21307/immunohematology-2019-279 Get It

Abstract The Mayo Clinic, in Rochester, Minnesota, recently set forth a directive to develop a Mayo Emergency Incident Command System (MEICS) plan to respond to major disasters. The MEICS plan that was developed interfaces with national response plans to ensure effective communication and coordination between our institution and local, state, and federal agencies to establish a common language and communication structure. The MEICS plan addresses multiple aspects of dealing with resource needs during a crisis, including the need for blood and transfusion medicine services. The MEICS plan was developed to supplement our current local emergency preparedness procedures and provide a mechanism for responding to the escalating severity of an emergency to deal with situations of a magnitude that is outside the normal experience. A plan was developed to interface the existing Transfusion Medicine disaster plan standard operating procedures (SOP) with the institutional and Department of Laboratory Medicine (DLMP) MEICS plans. The first step in developing this interface was defining MEICS. Other major steps were defining the chain of command, developing a method for visually indicating who is “in charge,” planning communication, defining the actions to be taken, assessing resource needs, developing flowcharts and updating SOPs, and developing a blood rationing team to deal with anticipated blood shortages. Several key features of the interface and updated disaster plan that were developed are calling trees for response personnel, plans for relocating leadership to alternative command centers, and action sheets to assist with resource assessment. The action sheets also provide documentation of key actions by response personnel. Immunohematology 2008;24:93–101 .
Development and validation of a fluorescent microsphere immunoassay for anti-IgA
Rumilla, Kandelaria M., Peterman, J.M., Jedynak, E.A., Homburger, H A, Winters, Jeffrey L.

Mayo Clinic

Immunohematology | May 20, 2021 | Volume: 25 | Issue: 1 | Pages: 24-28

10.21307/immunohematology-2019-227 Get It

Abstract Anti-IgA may cause anaphylactic transfusion reactions in IgA-deficient individuals. Testing for IgG anti-IgA is useful to identify persons at risk. This report describes an immunoassay for anti-IgA that uses polyclonal IgA coupled to fluorescent microspheres as an immunosorbent. Anti-IgA is detected by phycoerythrin-labeled anti-IgG. The assay is calibrated in arbitrary units by use of a serum that contains anti-IgA. Dose-response studies with sera that contain anti-IgA showed positive responses at dilutions up to 32-fold greater than the dilution used to test patients’ samples. Inhibition studies with purified IgA and IgA-deficient serum showed no inhibition with IgA-deficient serum and complete inhibition with soluble IgA. Clinical tests performed in more than 90 assays had a CV of 13.6 percent for measurements of an internal positive control. The fluorescent immunoassay method is rapid, reproducible, and sensitive to low concentrations of IgG anti-IgA. Immunohematology 2009;25:24–28.
Gender Distribution and Rates of Publication of Abstracts Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery Meeting Over a 25-Year Period
Tooley, Andrea A. , Tran, Ann Q. , Rebhun, Carl B., Paulose, Sefy A. , Lisman, Richard D. , Kim, Eleanore T. , Belinsky, Irina

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | May 20, 2021 | Volume: 37 | Issue: 3S | Pages: S125-S126

10.1097/iop.0000000000001873 | PMID 34011913 Get It

Vascular Spinal Cord Disorders
English, Stephen , Zalewski, Nicholas L. , English, Stephen W

Mayo Clinic

Seminars in Neurology | May 19, 2021 | Volume: 41 | Issue: 03 | Pages: 256-268

10.1055/s-0041-1725124 | PMID 34010968 Get It

AbstractVascular disorders of the spinal cord are uncommon yet under-recognized causes of myelopathy. Etiologies can be predominantly categorized into clinical and radiographic presentations of arterial ischemia, venous congestion/ischemia, hematomyelia, and extraparenchymal hemorrhage. While vascular myelopathies often produce significant morbidity, recent advances in the understanding and recognition of these disorders should continue to expedite diagnosis and proper management, and ideally improve patient outcomes. This article comprehensively reviews relevant spinal cord vascular anatomy, clinical features, radiographic findings, treatment, and prognosis of vascular disorders of the spinal cord.
Clinical and Radiologic Features, Pathology, and Treatment of Baló Concentric Sclerosis
Jolliffe, Evan, Guo, Yong , Hardy, Todd A. , Morris, Pearse , Lucchinetti, Claudia F. , Tobin, W. Oliver , Jolliffe, Evan A, Morris, P Pearse, Tobin, W Oliver , Hardy, Todd A , Flanagan, Eoin P.

Mayo Clinic

Neurology | May 19, 2021 | Volume: 97 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000012230 | PMID 34011576 Get It

In Memoriam Dr. Charles N. Aprill, MD
Bogduk, Nikolai , Maus, Tim

Mayo Clinic

Spine | May 19, 2021 | Volume: 46 | Issue: 15 | Pages: E800-E801

10.1097/brs.0000000000004120 Get It